
    
      The study will assess the safety and efficacy of umbralisib in combination with ublituximab
      in subjects with treatment na√Øve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma
      (SLL). Ublituximab will be administered through Cycle 12, while umbralisib will be
      administered through cycle 24. After this time, subjects will be followed for PFS.
    
  